Oncoinvent ASA Logo

Oncoinvent ASA

Developing alpha-emitting radiotherapies for treating cancers in the peritoneal cavity.

OCIN | Euronext Growth

Overview

Corporate Details

ISIN(s):
NO0010779341 (+1 more)
LEI:
54930076H5GUZRMSNR39
Country:
Norway
Address:
Gullhaugveien 7, 0484 Oslo
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Oncoinvent ASA is a clinical-stage biotechnology company dedicated to developing innovative radiopharmaceutical products for cancer treatment. The company's core focus is on direct alpha therapy. Its lead product candidate, Radspherin®, is an alpha-emitting therapeutic designed for treating cancers within the peritoneal cavity, such as metastatic colorectal and ovarian cancers. The technology utilizes biodegradable, inorganic microparticles as carriers for alpha-emitters, enabling the delivery of high-power, short-range radiation directly to tumors. This approach ensures regional retention of the effective radiation dose while minimizing systemic exposure. Oncoinvent is actively advancing its product pipeline through clinical trials, including a Phase 2 program for Radspherin® in ovarian cancer patients.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-11-27 12:59
Director's Dealing
Oncoinvent ASA: Notification of trade - primary insider/close associate - Attac…
English 141.1 KB
2025-11-27 12:59
Share Issue/Capital Change
Oncoinvent ASA: Notification of trade - primary insider/close associate - Attac…
English 65.7 KB
2025-11-27 12:59
Share Issue/Capital Change
Oncoinvent ASA: Notification of trade - primary insider/close associate
English 3.4 KB
2025-11-25 06:37
Share Issue/Capital Change
Oncoinvent ASA: Last day of trading in subscription rights
English 10.6 KB
2025-11-17 06:30
Share Issue/Capital Change
Oncoinvent ASA: Commencement of the subscription period for the Rights Issue
English 14.7 KB
2025-11-14 15:45
Regulatory News Service
Oncoinvent ASA: Notice of Extraordinary General Meeting in connection with the …
Norwegian 3.4 MB
2025-11-14 15:45
Pre-Annual General Meeting Information
Oncoinvent ASA: Notice of Extraordinary General Meeting in connection with the …
English 3.8 KB
2025-11-14 14:51
Director's Dealing
Oncoinvent ASA - Receipt of subscription rights in the rights issue by primary …
Norwegian 92.3 KB
2025-11-14 14:51
Share Issue/Capital Change
Oncoinvent ASA - Receipt of subscription rights in the rights issue by primary …
English 3.1 KB
2025-11-14 10:56
Director's Dealing
Oncoinvent ASA - Receipt of subscription rights in the rights issue by primary …
Norwegian 194.1 KB
2025-11-14 10:56
Director's Dealing
Oncoinvent ASA - Receipt of subscription rights in the rights issue by primary …
Norwegian 95.0 KB
2025-11-14 10:56
Share Issue/Capital Change
Oncoinvent ASA - Receipt of subscription rights in the rights issue by primary …
English 3.1 KB
2025-11-12 07:00
Share Issue/Capital Change
Oncoinvent ASA: EX. SUBSCRIPTION RIGHTS IN RIGHTS ISSUE TODAY
English 515 bytes
2025-11-11 18:16
Share Issue/Capital Change
Oncoinvent ASA: Terms of the underwritten Rights Issue
English 11.4 KB
2025-11-11 17:32
Share Issue/Capital Change
Oncoinvent ASA: Updated Key Information related to the contemplated Rights Issue
English 11.5 KB

Automate Your Workflow. Get a real-time feed of all Oncoinvent ASA filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Oncoinvent ASA

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Oncoinvent ASA via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

2cureX AB Logo
Predicts cancer drug response using 3D tumoroid tests to guide personalized oncology.
Sweden
2CUREX
4BASEBIO PLC Logo
Manufactures GMP-compliant synthetic DNA for advanced therapies, vaccines, and cell/gene therapies.
United Kingdom
4BB
4SC AG Logo
Developing small-molecule epigenetic drugs for high-need cancer indications.
Germany
VSC
60 DEGREES PHARMACEUTICALS, INC. Logo
Develops medicines for tropical diseases, including ARAKODA for malaria prevention.
United States of America
SXTP
89bio, Inc. Logo
Developing therapies for liver and cardiometabolic diseases like MASH and SHTG.
United States of America
ETNB
Aardvark Therapeutics, Inc. Logo
Developing oral drugs to suppress appetite for obesity and rare metabolic diseases.
United States of America
AARD
AbbVie Inc. Logo
A research-based biopharma firm creating medicines for immunology, oncology, and neuroscience.
United States of America
ABBV
ABEONA THERAPEUTICS INC. Logo
Developing AAV-based cell and gene therapies for serious and rare diseases.
United States of America
ABEO
Abera Bioscience AB Logo
Develops next-gen mucosal vaccines using its OMV platform, with a lead pneumococcal candidate.
Sweden
ABERA
ABINGDON HEALTH PLC Logo
A CDMO for lateral flow rapid tests, providing end-to-end services and its own branded products.
United Kingdom
ABDX

Talk to a Data Expert

Have a question? We'll get back to you promptly.